摘要
重症急性胰腺炎(SAP)是常见的消化系统危重疾病,有发病急、进展快、死亡率高等特点。低分子肝素(Low molecular weight heparins, LMWH)是一种常见的抗凝血酶制剂,同时在抗炎方面具有显著的作用,能抑制胰酶的产生、加速胰腺再生并改善胰腺微循环,从而提高SAP的生存率。但近几年有研究表明低分子肝素并不能显著降低SAP的手术率和死亡率。低分子肝素是否有利于急性重症胰腺炎的预后仍存在争议。本文就低分子肝素治疗SAP的治疗现状及进展做一综述,为临床上治疗SAP提供参考。
Severe acute pancreatitis (SAP) is a common critical disease of digestive system, which has the characteristics of acute onset, rapid progress and high mortality. Low molecular weight heparin (LMWH) is a common antithrombin preparation. At the same time, it plays a significant role in anti-inflammatory. It can inhibit the production of pancreatic enzyme, accelerate pancreatic regeneration and improve pancreatic microcirculation, so as to improve the survival rate of SAP. However, in recent years, studies have shown that low molecular weight heparin can not significantly reduce the operation rate and mortality of SAP. Whether low molecular weight heparin is beneficial to the prognosis of severe acute pancreatitis is still controversial. This paper reviews the current situation and progress of low molecular weight heparin in the treatment of sap, so as to provide reference for the clinical treatment of SAP.
出处
《临床医学进展》
2021年第11期5095-5100,共6页
Advances in Clinical Medicine
